Target Validation Information
Target ID T89534
Target Name Estrogen receptor
Target Type
Successful
Drug Potency against Target Tamoxifen Drug Info IC50 = 174 nM [552198]
6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 92 nM [527584]
4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol Drug Info IC50 = 50 nM [526457]
4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol Drug Info IC50 = 500 nM [526457]
4-(1,2-Diphenyl-but-1-enyl)-phenol Drug Info IC50 = 7 nM [526457]
7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol Drug Info IC50 = 6.8 nM [527198]
GSK-5182 Drug Info IC50 = 320 nM [527895]
ONAPRISTONE Drug Info Ki < 20 nM [534119]
8-n-pentylnaringenin Drug Info IC50 = 383 nM [528557]
DIHYDRORALOXIFENE Drug Info IC50 = 0.52 nM [525493]
Tamoxifen isopropyl bromide Drug Info Ki = 25.43 nM [531028]
BITHIONOL Drug Info IC50 = 3940.88 nM [531262]
8-methylnaringenin Drug Info IC50 = 5245 nM [528557]
4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol Drug Info IC50 = 18 nM [527327]
8-n-undecylnaringenin Drug Info IC50 = 1017 nM [528557]
8-n-heptylnaringenin Drug Info IC50 = 392 nM [528557]
8-n-nonylnaringenin Drug Info IC50 = 436 nM [528557]
8-(2,2-dimethylpropyl)naringenin Drug Info IC50 = 216 nM [528557]
4-(2-phenyl-1H-indol-3-yl)phenol Drug Info IC50 = 24 nM [527797]
4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol Drug Info IC50 = 94.8 nM [527797]
1-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 91 nM [527584]
6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol Drug Info IC50 = 709 nM [527584]
JNJ-26529152 Drug Info IC50 = 10 nM [530079]
6-Phenyl-naphthalen-2-ol Drug Info IC50 = 1345 nM [527584]
4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol Drug Info IC50 = 6100 nM [527232]
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 5280 nM [527232]
3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Drug Info IC50 = 5110 nM [527232]
2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol Drug Info IC50 = 504 nM [527681]
6-(4-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 211 nM [527681]
7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 537 nM [527232]
2,3-diphenyl-1H-indole Drug Info IC50 = 6950 nM [527797]
2-(4-Hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 1775 nM [527681]
4-(3-phenyl-1H-indol-2-yl)phenol Drug Info IC50 = 8310 nM [527797]
6-(3-Hydroxy-phenyl)-naphthalen-1-ol Drug Info IC50 = 1452 nM [527584]
4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol Drug Info IC50 = 10 nM [526589]
4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol Drug Info IC50 = 200 nM [526589]
5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 1140 nM [527681]
2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol Drug Info IC50 = 483 nM [527198]
6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 10 nM [527584]
5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 632 nM [527681]
6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 10.3 nM [527584]
2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol Drug Info IC50 = 447 nM [527232]
6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 24 nM [527584]
1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 266 nM [527584]
6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 92 nM [527584]
6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 174 nM [527584]
4,10-dimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 1030 nM [527966]
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol Drug Info IC50 = 780 nM [527232]
7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 727 nM [527232]
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol Drug Info IC50 = 819 nM [527232]
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol Drug Info IC50 = 153 nM [527232]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol Drug Info IC50 = 22 nM [527584]
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 8430 nM [527232]
2-Naphthalen-1-yl-benzooxazol-6-ol Drug Info IC50 = 1880 nM [527232]
2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol Drug Info IC50 = 390 nM [527232]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 230 nM [527584]
2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol Drug Info IC50 = 2557 nM [527232]
2-(4-Hydroxy-phenyl)-benzofuran-5-ol Drug Info IC50 = 176 nM [527232]
2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 3240 nM [527232]
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Drug Info IC50 = 35 nM [527232]
7-Bromo-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 155 nM [527232]
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol Drug Info IC50 = 16 nM [526532]
4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol Drug Info IC50 = 70 nM [526589]
5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 2765 nM [527232]
3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 1170 nM [527966]
8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 22 nM [527584]
6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol Drug Info IC50 = 282 nM [527584]
3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 654 nM [527966]
N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine Drug Info IC50 = 2400 nM [529687]
6-butyl-2,4-dipropylaminopyrimidine Drug Info IC50 = 13000 nM [529687]
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Drug Info IC50 = 815 nM [527232]
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 1570 nM [527232]
Clomifene Drug Info EC50 = 179 nM [552799]
MPrP Drug Info IC50 = 20 nM [529813]
Estriol Drug Info EC50 = 12 nM [552450]
Conjugated Estrogens Drug Info EC50 = 1.1 nM [552450]
JNJ-17148066 Drug Info IC50 = 11 nM [530079]
SOPHORAFLAVANONE B Drug Info IC50 = 57 nM [528557]
Afimoxifene Drug Info IC50 = 40 nM [529739]
8-n-propylnaringenin Drug Info IC50 = 155 nM [528557]
8-(2-methylpropyl)naringenin Drug Info IC50 = 80 nM [528557]
Tamoxifen methyl iodide Drug Info Ki = 46.29 nM [531028]
8-benzylnaringenin Drug Info IC50 = 503 nM [528557]
4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol Drug Info IC50 = 1800 nM [527797]
2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Drug Info IC50 = 117 nM [527232]
4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol Drug Info IC50 = 150 nM [526457]
6-ethyl-2,4-diisobutylaminopyrimidine Drug Info IC50 = 7300 nM [529687]
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol Drug Info IC50 = 3800 nM [527232]
1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 43 nM [527584]
6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol Drug Info IC50 = 884 nM [527584]
6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol Drug Info IC50 = 1231 nM [527584]
2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 139 nM [527232]
7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 481 nM [527232]
2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol Drug Info IC50 = 1200 nM [527232]
2,4-Dibenzylamino-6-isopentylpyrimidine Drug Info IC50 = 8300 nM [529687]
4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 1500 nM [527681]
2-(4-Hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 1227 nM [527232]
4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 335 nM [527966]
6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 464 nM [527232]
2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol Drug Info IC50 = 6630 nM [527681]
4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol Drug Info IC50 = 52 nM [527327]
4-benzyl-2,6-diisobutylamino-pyrimidine Drug Info IC50 = 9500 nM [529687]
4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 634 nM [527681]
WAY-169916 Drug Info IC50 = 1300 nM [527327]
7-(4-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 442 nM [527584]
4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide Drug Info IC50 = 1371 nM [527880]
2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol Drug Info IC50 = 114 nM [527198]
4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol Drug Info IC50 = 15 nM [526589]
3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 585 nM [527966]
6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 27 nM [527584]
4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 468 nM [527966]
N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide Drug Info IC50 = 404 nM [527880]
4-Naphthalen-2-yl-phenol Drug Info IC50 = 638 nM [527584]
2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol Drug Info IC50 = 775 nM [527232]
3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Drug Info IC50 = 2353 nM [527232]
1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 77 nM [527584]
7-Phenyl-naphthalen-2-ol Drug Info IC50 = 3405 nM [527584]
4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide Drug Info IC50 = 871 nM [527880]
Pipendoxifene Drug Info IC50 = 1.5 nM [526057]
3-chloro-4-(4-hydroxyphenyl)salicylaldoxime Drug Info Ki = 310 nM [529314]
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 5000 nM [527232]
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Drug Info IC50 = 82 nM [527232]
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Drug Info IC50 = 2410 nM [527232]
2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol Drug Info IC50 = 1300 nM [527232]
7-(3-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2642 nM [527584]
4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Drug Info IC50 = 190 nM [527232]
3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Drug Info IC50 = 3000 nM [527232]
EFFUSOL Drug Info IC50 = 240 nM [527966]
4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol Drug Info IC50 = 25 nM [527327]
7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 498 nM [527232]
2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Drug Info IC50 = 1900 nM [527232]
4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 1210 nM [527966]
N-butyl-4-hydroxy-N-phenylbenzenesulfonamide Drug Info IC50 = 317 nM [527880]
6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 101 nM [527966]
4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 237 nM [527966]
4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol Drug Info IC50 = 37 nM [527327]
2-(4-Hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 902 nM [527232]
4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol Drug Info IC50 = 30 nM [526457]
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Drug Info IC50 = 34 nM [526532]
4-hydroxy-N,N-diphenylbenzenesulfonamide Drug Info IC50 = 410 nM [527880]
8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 30 nM [527584]
4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 4610 nM [527966]
6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol Drug Info IC50 = 40 nM [527584]
4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol Drug Info IC50 = 15 nM [526457]
6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 107 nM [527584]
4-hydroxy-N-phenyl-N-propylbenzenesulfonamide Drug Info IC50 = 303 nM [527880]
4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol Drug Info IC50 = 40 nM [527327]
Estradiol Drug Info Ec50 = 40 nM [553259]
Fulvestrant Drug Info IC50 = 9.35 nM
4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol Drug Info IC50 = 18 nM [527327]
Tamoxifen ethyl bromide Drug Info Ki = 13.66 nM [531028]
Estrogen platinum(II) hybrid derivative Drug Info IC50 = 2800 nM [527267]
Tamoxifen butyl bromide Drug Info Ki = 13.01 nM [531028]
ZK-164015 Drug Info IC50 = 1.4 nM [527179]
JNJ-26529126 Drug Info IC50 = 1210 nM [530079]
4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 212 nM [527681]
4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol Drug Info IC50 = 105 nM [527327]
4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol Drug Info IC50 = 240 nM [526589]
N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide Drug Info IC50 = 500 nM [527880]
Lasofoxifene Drug Info IC50 = 1.2 nM [552217]
N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide Drug Info IC50 = 866 nM [527880]
JNJ-19398990 Drug Info IC50 = 1736 nM [530079]
Diethylstilbestrol Drug Info Ki = 870 nM [552586]
7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol Drug Info IC50 = 1.5 nM [527198]
4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 213 nM [527681]
2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Drug Info IC50 = 4.3 nM [526532]
1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol Drug Info Ki = 8.5 nM [527738]
[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime Drug Info Ki = 0.15 nM [526711]
Carboron Cluster with phenol Drug Info IC50 = 0.59 nM [526873]
DIADZEIN Drug Info IC50 = 17000 nM [526493]
HEXESTROL Drug Info IC50 = 2 nM
ARZOXIFENE Drug Info IC50 = 21.5 nM [528827]
8-(3-methylbutyl)naringenin Drug Info IC50 = 140 nM [528557]
3'-Methoxy-4'Hydroxyclomiphene Drug Info IC50 = 780 nM [533383]
4',5,7-trihydroxy-6,8-dimethylisoflavone Drug Info IC50 = 10200 nM [526493]
Mestranol Drug Info EC50 = 9.1 nM [552450]
COUMESTROL Drug Info IC50 = 75.7 nM [527550]
BROUSSONIN A Drug Info IC50 = 8100 nM [530935]
LTERHKILHRLLQEGSPSD Drug Info Ki = 190 nM [528885]
Toremifene Drug Info IC50 = 1000 nM [529105]
5-hydroxy-2-phenylisoindoline-1,3-dione Drug Info IC50 = 2700 nM [528481]
ANDROSTENEDIOL Drug Info IC50 = 180 nM [529061]
NAFOXIDINE Drug Info IC50 = 40.9 nM [534677]
Dienestrol Drug Info EC50 = 1.1 nM [552450]
Danazol Drug Info IC50 = 57400 nM
Mitotane Drug Info IC50 = 318000 nM [552388]
2,4-diisobutylamino-6-isopentylpyrimidine Drug Info IC50 = 3100 nM [529687]
Doxorubicin-Formaldehyde Conjugate Drug Info IC50 = 300 nM [526966]
2-phenyl-1,2'-spirobi[1H-indene]-5'-ol Drug Info IC50 = 114 nM [526532]
Geldanamycin-estradiol hybrid Drug Info IC50 = 80 nM [525501]
N-allyl-4-hydroxy-N-phenylbenzenesulfonamide Drug Info IC50 = 235 nM [527880]
Action against Disease Model Fulvestrant IC50 in immortalized rat embryonic hypothalamic cell line D12 subclone cells: 0.63 nM [552198] Drug Info
Tamoxifen IC50 in immortalized rat embryonic hypothalamic cell line D12 subclone cells: 174 nM [552198] Drug Info
References
Ref 552198Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology. 1999 Sep;140(9):3928-37.
Ref 552198Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology. 1999 Sep;140(9):3928-37.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526457J Med Chem. 2002 Nov 21;45(24):5358-64.Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Ref 526457J Med Chem. 2002 Nov 21;45(24):5358-64.Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Ref 526457J Med Chem. 2002 Nov 21;45(24):5358-64.Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527895Bioorg Med Chem Lett. 2006 Feb 15;16(4):821-4. Epub 2005 Nov 22.Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
Ref 534119J Med Chem. 1996 Apr 26;39(9):1778-89.Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 525493Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40.Synthesis and biological activity of trans-2,3-dihydroraloxifene.
Ref 531028Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. Epub 2010 Jun 20.Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha.
Ref 531262Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 530079J Med Chem. 2009 Dec 10;52(23):7544-69.Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 529687J Med Chem. 2008 Oct 23;51(20):6512-30. Epub 2008 Sep 12.Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.
Ref 529687J Med Chem. 2008 Oct 23;51(20):6512-30. Epub 2008 Sep 12.Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 552198Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology. 1999 Sep;140(9):3928-37.
Ref 552799Interaction of stilbene compounds with human and rainbow trout estrogen receptors. Environ Toxicol Chem. 2008 Feb;27(2):442-51. doi: 10.1897/07-146R.1.
Ref 529813Bioorg Med Chem Lett. 2009 Jan 1;19(1):108-10. Epub 2008 Nov 6.Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity.
Ref 552450Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109.
Ref 552450Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109.
Ref 530079J Med Chem. 2009 Dec 10;52(23):7544-69.Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 529739Bioorg Med Chem. 2008 Nov 1;16(21):9554-73. Epub 2008 Sep 16.Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 531028Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. Epub 2010 Jun 20.Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 526457J Med Chem. 2002 Nov 21;45(24):5358-64.Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Ref 529687J Med Chem. 2008 Oct 23;51(20):6512-30. Epub 2008 Sep 12.Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 529687J Med Chem. 2008 Oct 23;51(20):6512-30. Epub 2008 Sep 12.Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 529687J Med Chem. 2008 Oct 23;51(20):6512-30. Epub 2008 Sep 12.Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 526057J Med Chem. 2001 May 24;44(11):1654-7.Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.
Ref 529314J Med Chem. 2008 Mar 13;51(5):1344-51. Epub 2008 Feb 13.Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 526457J Med Chem. 2002 Nov 21;45(24):5358-64.Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526457J Med Chem. 2002 Nov 21;45(24):5358-64.Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 553259Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997 Nov;11(12):1868-78.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 531028Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. Epub 2010 Jun 20.Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha.
Ref 527267Bioorg Med Chem Lett. 2004 Dec 6;14(23):5919-24.Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies.
Ref 531028Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. Epub 2010 Jun 20.Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha.
Ref 527179Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63.Synthesis and biological evaluation of stilbene-based pure estrogen antagonists.
Ref 530079J Med Chem. 2009 Dec 10;52(23):7544-69.Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 552217Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology. 2000 Apr;141(4):1338-44.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Ref 530079J Med Chem. 2009 Dec 10;52(23):7544-69.Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Ref 552586Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem. 2006;6(3):203-15.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 527738J Med Chem. 2005 Sep 22;48(19):5989-6003.Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
Ref 526711J Med Chem. 2003 Sep 11;46(19):4032-42.Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process.
Ref 526873Bioorg Med Chem Lett. 2003 Nov 17;13(22):4089-92.Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types of carboranyl groups.
Ref 526493J Nat Prod. 2002 Dec;65(12):1749-53.Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
Ref 528827J Med Chem. 2007 May 31;50(11):2682-92. Epub 2007 May 10.Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 533383J Med Chem. 1989 Jan;32(1):192-7.Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects in MCF 7 breast cancer cells.
Ref 526493J Nat Prod. 2002 Dec;65(12):1749-53.Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
Ref 552450Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109.
Ref 527550J Med Chem. 2005 May 19;48(10):3463-6.Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
Ref 530935Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. Epub 2010 Apr 19.New estrogenic compounds isolated from Broussonetia kazinoki.
Ref 528885Bioorg Med Chem Lett. 2007 Aug 1;17(15):4118-22. Epub 2007 May 23.Bicyclo[2.2.2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators.
Ref 529105J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7. Epub 2007 Sep 7.Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
Ref 528481Bioorg Med Chem Lett. 2007 Jan 1;17(1):118-22. Epub 2006 Oct 1.Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones.
Ref 529061Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8. Epub 2007 Sep 7.Androstene-3,5-dienes as ER-beta selective SERMs.
Ref 534677J Med Chem. 1998 Jul 30;41(16):2928-31.Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Ref 552450Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109.
Ref 552388Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem. 2004 Feb;378(3):664-9. Epub 2003 Oct 25.
Ref 529687J Med Chem. 2008 Oct 23;51(20):6512-30. Epub 2008 Sep 12.Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.
Ref 526966J Med Chem. 2004 Feb 26;47(5):1193-206.Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 525501Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.Synthesis and evaluation of geldanamycin-estradiol hybrids.
Ref 527880Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. Epub 2005 Nov 21.Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.